Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Their proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Their initial focus is to advance RCT™ product…More candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. They plan to file their first Investigational New Drug application (IND) for RTX-134 in phenylketonuria during the first quarter of 2019. They are planning to file additional INDs in rare diseases, cancer and autoimmune diseases in 2019, 2020 and beyond.